Day: April 9, 2020

IRVING, Texas, April 09, 2020 (GLOBE NEWSWIRE) — Blucora, Inc. (NASDAQ: BCOR), a leading provider of tax-smart financial solutions that empower people to achieve their financial goals, today announced it has entered into an amended agreement to acquire privately held HK Financial Services (HKFS). The parties mutually agreed to enter into the amended agreement in response to current economic conditions.  The amended agreement adjusts the purchase price to $100 million, from $160 million, while also adding a financing contingency and setting a new target closing window between today and October 1, 2020. The amended agreement allows for the closing window to be extended upon mutual agreement, as well as the potential for performance-based earn-out payments over time, should the asset targets from the original agreement be achieved.We...

TORONTO and CAMBRIDGE, Mass., April 09, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegenerative diseases, announced today that the journal Neurology will publish AAN abstracts of data that demonstrate the strength of its antibody programs for Parkinson’s disease/alpha-synuclein (a-syn) and amyotrophic lateral sclerosis (ALS)/TDP-43. The data will appear in the April 14 online supplement to Neurology, the most widely read, highly cited peer-reviewed neurology journal.Publication in Neurology closely follows the Alzheimer’s Association International Conference® (AAIC®) acceptance of several abstracts for its annual conference. Both acceptances...

Newport Beach, Calif., April 08, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) (“DPW” or the “Company”), a diversified holding company announced today that, due to the emerging public health impact of the coronavirus (COVID-19) pandemic, the location of DPW’s special meeting of stockholders that was originally scheduled to be held on Tuesday, March 31, 2020 at 9:00 a.m. PT at the Hyatt Regency Hotel Newport Beach, located at 1107 Jamboree Road, Newport Beach, CA 92660 (the “Special Meeting”) has been changed and will be held in a virtual meeting format only on April 30, 2020 at 9:00 a.m. PT.The Special Meeting will be held for the following purposes:To approve the issuance of shares of the Corporation’s Class A common stock, par value $0.001 per share (“Common Stock”) to Esousa Holdings LLC (“Esousa”), in accordance...

VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) — Rugby Mining Limited (“Rugby” or the “Company”) (TSX-V: RUG) reports that the Company is temporarily suspending its exploration operations and reducing expenditures, including salaries in response to the COVID-19 virus outbreak.Mr. Bryce Roxburgh, the Company’s President and CEO stated, “The safety of our employees, consultants and contractors is of the utmost importance. Very importantly, I would like to sincerely thank all our employees who have voluntarily accepted substantial salary cuts”.Mr. Roxburgh continued, “Rugby will continue to monitor the situation and remains dedicated to following health protocols to protect personnel. When it is safe to do so, exploration will recommence.“In the meantime, we are awaiting results from sampling at El Zanjon, Argentina (see...

BBS-Bioactive Bone Substitutes Plc. has published its audited Financial Statements for 2019 at http://www.bbs-artebone.fi/investors/financial-reports/The Financial Statements is also attached to this release.BBS-Bioactive Bone Substitutes PlcMore informationIlkka Kangasniemi, CEOtel. 040 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fiHannu Säynäjäkangas, CFOtel. 040 5021092, e-mail: hannu.saynajakangas@bbs-artebone.fiCertified Advisor:Stockholm Certified Advisers AB, p. +46 70 5516 729, info@certifiedadviser.seDISTRIBUTION:Nasdaq Helsinki OyNasdaq Stockholm ABKey mediawww.bbs-artebone.fiThis is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 9th April 2020...

BBS-Bioactive Bone Substitutes Oyj on julkaissut vuoden 2019 tilintarkastetun tilinpäätöksen yhtiön internet-sivuilla osoitteessahttp://www.bbs-artebone.fi/sijoittajille/sijoittajilletaloudelliset-raportit/Tilinpäätös on myös tämän tiedotteen liitteenä.BBS-Bioactive Bone Substitutes OyjLisätietoja antavat:Ilkka Kangasniemi, toimitusjohtajapuh. +35840 7080 307, s-posti: ilkka.kangasniemi@bbs-artebone.fiHannu Säynäjäkangas, talousjohtajapuh. 040 5021092, s-posti: hannu.saynajakangas@bbs-artebone.fiHyväksytty neuvonantaja:Stockholm Certified Advisers AB, p. +46 70 5516 729, info@certifiedadviser.seJAKELU:Nasdaq Helsinki OyNasdaq Stockholm ABKeskeiset tiedotusvälineetwww.bbs-artebone.fiTämä on tieto, jonka BBS-Bioactive Bone Substitutes Oyj on velvollinen julkistamaan EU:n markkinoiden väärinkäytön asetuksen mukaisesti. Tiedot on toimitettu...

Rovio Entertainment Corporation                  Press Release                 April 9, 2020The publishing time for Q1 2020 interim reportRovio Entertainment Corporation will publish its Q1 2020 interim report on April 28th, 2020 at 9:00 a.m. EEST.Rovio will host an English language audiocast and phone conference on Q1 2020 financial results for analysts, media and institutional investors on April 28th 2020 at 2:00 p.m. EEST.The audiocast can be viewed live at: https://investors.rovio.com/en , and later on the same day as a recording.Dial in numbers for the phone conference will be visible in company website closer to the interim report publishing date.Rovio Entertainment Corp. follows a silent period of 30 days prior to the publication of its financial reports.ROVIO ENTERTAINMENT CORPORATIONMore information:Veli-Pekka Puolakanaho, IR...

Rovio Entertainment Oyj                        Lehdistötiedote                    9.4.2020 Q1 2020 osavuosikatsauksen julkaisuajankohtaRovio Entertainment Oyj julkaisee vuoden 2020 ensimmäistä vuosineljännestä koskevan osavuosikatsauksensa 28.4.2020 klo 9.00.Rovio järjestää vuoden 2020 ensimmäistä vuosineljännestä koskevan englanninkielisen audiocastin ja puhelinkonferenssin analyytikoille, lehdistölle ja instituutionaalisille sijoittajille 28.4.2020 klo 14.00.Audiocast on katsottavissa suorana osoitteessa https://investors.rovio.com/fi , ja myöhemmin tallenteena yhtiön verkkosivuilla.Puhelinkonferenssin numerot ilmoitetaan yhtiön verkkosivuilla lähempänä raportin julkaisuajankohtaa.Rovio Entertainment Oyj noudattaa 30 päivän hiljaista jaksoa ennen osavuosikatsauksen julkistamista.ROVIO ENTERTAINMENT OYJLisätietoja:Veli-Pekka Puolakanaho,...

RANCHO CUCAMONGA, April 09, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:50 p.m. Eastern Time.This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products....

VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a patient with severe COVID-19 under the care of a leading medical center in Southern California exhibited clinical improvement after treatment with the Company’s investigational new drug, leronlimab. The patient was intubated and in critical condition in the ICU, and had received an IL-6 blocking agent four days earlier without apparent benefit. Concomitantly, the patient also received either an antiretroviral agent or placebo as part of an unrelated clinical trial. With no clinical improvement observed over the ensuing four days, the patient then received...